Literature DB >> 15525458

Tissue distribution of bitespiramycin and spiramycin in rats.

Xiang-guo Shi1, Yu-ming Sun, Yu-feng Zhang, Da-fang Zhong.   

Abstract

AIM: To investigate the tissue distribution of bitespiramycin (BSPM) and spiramycin (SPM) in rats.
METHODS: Liquid chromatographic-mass spectrometric assay was applied for the determination of three major components (isovalerylspiramycins, ISV-SPMs) of BSPM and their major active metabolites (SPMs) in rat tissues and plasma after an oral dose of bitespiramycin, as well as SPMs.
RESULTS: High levels of drug concentrations were observed in most tissues, especially in the liver, stomach, intestine, spleen, lung, womb, and pancreas. BSPM persisted long time in many rat tissues such that the drug concentration in spleen was 69.4 nmol/g at 60 h post-dose and it was still above the minimum inhibitory concentration of many susceptible pathogens. At 2.5 h post-dose, the total concentrations of ISV-SPMs and SPMs achieved in tissues were from 6 to 215 times higher than the corresponding concentrations in plasma. At 2.5 h post-dose, the mean C(t)/C(p) of BSPM appeared to be 2- or 3-fold those of SPM in most tissues. The tissue to plasma concentration ratios following oral dose of BSPM were higher than those of SPM in most tissues. The drug was not detected in brain and testis after a single dose of BSPM and SPM.
CONCLUSION: Both BSPM and SPM penetrate into rat tissues well and BSPM has higher tissue affinity than SPM.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15525458

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  3 in total

1.  Significant reduction of brain cysts caused by Toxoplasma gondii after treatment with spiramycin coadministered with metronidazole in a mouse model of chronic toxoplasmosis.

Authors:  Wai Kit Chew; Ignacio Segarra; Stephen Ambu; Joon Wah Mak
Journal:  Antimicrob Agents Chemother       Date:  2012-01-23       Impact factor: 5.191

2.  Roles of P-glycoprotein, Bcrp, and Mrp2 in biliary excretion of spiramycin in mice.

Authors:  Xianbin Tian; Jun Li; Maciej J Zamek-Gliszczynski; Arlene S Bridges; Peijin Zhang; Nita J Patel; Thomas J Raub; Gary M Pollack; Kim L R Brouwer
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

3.  Repurposing CFDA-approved drug carrimycin as an antiviral agent against human coronaviruses, including the currently pandemic SARS-CoV-2.

Authors:  Haiyan Yan; Jing Sun; Kun Wang; Huiqiang Wang; Shuo Wu; Linlin Bao; Weiqing He; Dong Wang; Airu Zhu; Tian Zhang; Rongmei Gao; Biao Dong; Jianrui Li; Lu Yang; Ming Zhong; Qi Lv; Feifei Qin; Zhen Zhuang; Xiaofang Huang; Xinyi Yang; Yuhuan Li; Yongsheng Che; Jiandong Jiang
Journal:  Acta Pharm Sin B       Date:  2021-03-11       Impact factor: 11.413

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.